Xenon Pharmaceuticals (XENE) Other Operating Expenses (2014 - 2026)

Xenon Pharmaceuticals (XENE) has reported Other Operating Expenses for 6 consecutive years, with $76.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Operating Expenses rose 377.18% year-over-year to $76.5 million; the TTM figure through Mar 2026 stood at -$61.4 million (up 85.07% YoY), while the FY2025 annual figure was -$119.3 million, down 14.89% from the prior year.
• Other Operating Expenses rose to $76.5 million in Q1 2026 per XENE's latest filing, from -$101.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $98.5 million in Q4 2022 and bottomed at -$229.8 million in Q4 2024.
• Historically, Other Operating Expenses has averaged -$37.9 million across 4 years, with a median of -$28.9 million in 2025.
• Annual changes were most pronounced in 2025 — Other Operating Expenses sank 463.42% — and 2026, when it soared 377.18%.
• Xenon Pharmaceuticals' Other Operating Expenses stood at $98.5 million in 2022, then slumped by 333.35% to -$229.8 million in 2024, then surged by 56.05% to -$101.0 million in 2025, then jumped by 175.74% to $76.5 million in 2026.
• Business Quant data shows XENE's Other Operating Expenses at $76.5 million in Q1 2026, -$101.0 million in Q4 2025, and -$6.7 million in Q3 2025.